CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1

First Page		Document Content
Date: 2013-01-20 11:10:44 Tyrosine kinases Pyridines Pyrimidines Tyrosine kinase receptors Tyrosine kinase Tyrosine-kinase inhibitor Signal transduction Quizartinib CD135 Biology Cell signaling Organic chemistry		CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1 Add to Reading List Source URL: www.gistsupport.org Download Document from Source Website File Size: 765,48 KB Share Document on Facebook

	The TKI Tool More Than Conflict Management ce n DocID: 1rdnE - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document
	TECHNOLOGY OFFER A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent DocID: 1pWe8 - View Document
	Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra DocID: 1pvTL - View Document
	Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis DocID: 1p0SG - View Document